A secretive Silicon Valley startup has been quietly pitching investors and elite longevity conferences on one of the most ethically charged propositions in modern biotechnology: growing brainless cloned human bodies as organ sources and potential vessels for brain transplantation, as reported by MIT Technology Review.
The public face vs. the private pitch
R3 Bio, founded by John Schloendorn, publicly presents itself as a company focused on creating nonsentient monkey “organ sacks” as alternatives to animal testing, as previously covered by Wired. But MIT Technology Review’s investigation uncovered a more ambitious agenda: Schloendorn has actively pitched “brainless clones” — cloned human bodies engineered with minimal brain structure — to serve as immunologically perfect organ sources or, ultimately, as hosts for brain transplants in pursuit of radical life extension.
The company reportedly presented a session titled “Full Body Replacement” at Abundance Longevity, a high-priced event in Boston last September. R3 Bio denies publicly discussing brainless human clones, despite the evidence gathered by MIT Technology Review, including reports of a 2023 internal letter outlining a technical road map for “body replacement cloning” and a confidential online seminar called the Body Replacement Mini Conference.
Billionaire backing and government ties
The startup has reportedly attracted funding from billionaire Tim Draper, the Singapore-based Immortal Dragons fund, and life-extension investors LongGame Ventures. Perhaps more notable is R3 Bio’s relationship with ARPA-H, the US government’s Advanced Research Projects Agency for Health. R3 appears to have connections with ARPA-H, and program manager Jean Hébert described an informal but “very collaborative” relationship with Schloendorn, telling MIT Technology Review: “It’s a perfect match, right? Body, brain.”
The science gap
The distance between R3 Bio’s vision and current scientific capability is vast. According to MIT Technology Review’s findings, the company has not cloned anything larger than a rodent. No human has ever been cloned, though it is considered theoretically possible. Since early efforts to clone human embryos more than two decades ago, mammalian cloning has advanced to include dogs, cats, horses, and cattle — but scaling to primates, let alone engineering brain-suppressed human clones, remains well beyond demonstrated capability.
Scientific alarm
Jose Cibelli, a Michigan State University researcher who was among the first scientists to attempt human embryo cloning, offered a blunt assessment: “It sounds crazy, in my opinion. How do you demonstrate safety? What is safety when you’re trying to create an abnormal human?” He added: “There is no limit to human imagination and ways to make money, but there have to be boundaries. And this is the boundary of making a human being who is not a human being.”
The structural picture
The story of R3 Bio sits at an instructive intersection: the longevity industry’s growing capital flows, a regulatory environment still catching up to cloning-adjacent technologies, and the institutional incentives that allow ambitious biotech claims to attract serious money before demonstrating serious science. That a company with no primate cloning capability can secure billionaire funding, present at exclusive conferences, and cultivate government relationships speaks to the structural dynamics of longevity investing — where the promise of defeating death commands a premium that outpaces scrutiny.
Feature image by Tara Winstead on Pexels
